A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability, and Pharmacokinetics of TKM-100802 in Healthy Human Volunteers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs TKM Ebola (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors Arbutus Biopharma
- 06 Aug 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 28 May 2015 Planned number of patients changed from 28 to 20 as reported by ClinicalTrials.gov
- 28 May 2015 Planned End Date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov